{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:13Z","timestamp":1787026573414,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in the treatment of resectable and advanced gastric cancer. However, their effectiveness in initially unresectable gastric cancer remains unclear. This study aims to evaluate the efficacy and elucidate the molecular mechanisms of conversion therapy utilizing ICIs in patients with initially unresectable gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients with initially unresectable locally advanced or oligometastatic gastric cancer treated with ICIs-based therapy for conversion purposes. The primary endpoints were rates of complete pathological response (pCR), major pathological response (MPR), and R0 resection. Secondary endpoints included overall survival (OS), disease-free survival (DFS), event-free survival (EFS) and safety. A multi-omics analysis was performed on the tumor samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 73 patients were analyzed, with 75.3% at stage cIV. The median EFS and OS were 26.1 and 41.3 months, respectively. 82.2% of the patients underwent radical surgery and achieved a median EFS of 30.9 months. The pCR and MPR rates were 24.7% and 37.0%, respectively. R0 resection was associated with superior survival, and MPR further enhanced efficacy. The incidence of adverse effects and postoperative complications were within acceptable limits. KMT2D mutations were associated with improved outcomes and enhanced immune responses, whereas tumor cytochrome P450 was linked to resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICIs-based conversion therapy demonstrates promising survival benefits and manageable safety profiles for patients with unresectable locally advanced or oligometastatic gastric cancer, and provides real-world evidence for a potential treatment strategy. Additionally, multi-omics findings have revealed drug resistance mechanisms and potential biomarkers of efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1753749","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:35:19Z","timestamp":1768286119000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Song","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duanbo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodi","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1016\/S2468-2667(21)00157-2","article-title":"Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study","volume":"6","author":"Zeng","year":"2021","journal-title":"Lancet Public Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0809-y","article-title":"A multicenter, randomized trial comparing efficacy and safety of paclitaxel\/capecitabine and cisplatin\/capecitabine in advanced gastric cancer","volume":"21","author":"Lu","year":"2018","journal-title":"Gastric Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-020-02222-0","article-title":"Current status of conversion surgery for stage IV gastric cancer","volume":"51","author":"Kinoshita","year":"2021","journal-title":"Surg Today"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1002\/mef2.56","article-title":"Chemoimmunotherapy for esophageal squamous cell carcinoma\u2014Summary and discussion of recent clinical trials","volume":"2","author":"Zhang","year":"2023","journal-title":"MedComm \u2013 Future Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1002\/mef2.79","article-title":"Current progress in chimeric antigen receptor T-cell therapy for Malignant tumors","volume":"3","author":"Zheng","year":"2024","journal-title":"MedComm \u2013 Future Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer","volume-title":"N Engl J Med","author":"Janjigian","year":"2025"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00795","article-title":"Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV\/CAP 05)","volume-title":"J Clin Oncol","author":"Li","year":"2025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09925-3","article-title":"Gastric cancer: a comprehensive review of current and future treatment strategies","volume":"39","author":"Sexton","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00975","article-title":"Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II\/III DANTE\/IKF-s633 Trial","volume":"42","author":"Lorenzen","year":"2024","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4050","article-title":"Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric\/gastroesophageal junction (GEJ) adenocarcinoma","volume":"39","author":"Li","year":"2026","journal-title":"J Clin Oncol."},{"key":"B18","article-title":"Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma","volume-title":"J Clin Oncol","author":"Li","year":"2026"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-016-0633-1","article-title":"Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study","volume":"20","author":"Sato","year":"2017","journal-title":"Gastric Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-017-0738-1","article-title":"The long-term survival of stage IV gastric cancer patients with conversion therapy","volume":"21","author":"Yamaguchi","year":"2018","journal-title":"Gastric Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-13143-w","article-title":"Neoadjuvant therapy with immune checkpoint inhibitors in gastric cancer: A systematic review and meta-analysis","volume":"30","author":"Li","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000316","article-title":"Positive status of epstein-barr virus as a biomarker for gastric cancer immunotherapy: A prospective observational study","volume":"43","author":"Xie","year":"2020","journal-title":"J Immunother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0121","article-title":"Association of tumor mutational burden with efficacy of pembrolizumab \u00b1 Chemotherapy as first-line therapy for gastric cancer in the phase III KEYNOTE-062 study","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e13629","article-title":"Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma","volume":"9","author":"Liu","year":"2023","journal-title":"Heliyon"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1448","article-title":"CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade","volume":"10","author":"Wang","year":"2020","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.09.004","article-title":"Small molecule inhibitors of the prostate cancer target KMT2D","volume":"533","author":"Yu","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00280-020-04181-2","article-title":"Involvement of cytochrome P450 enzymes in inflammation and cancer: a review","volume":"87","author":"Stipp","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41419-023-05803-2","article-title":"CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer","volume":"14","author":"Chen","year":"2023","journal-title":"Cell Death Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13046-023-02647-8","article-title":"Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer","volume":"42","author":"Liu","year":"2023","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1753749\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T06:35:23Z","timestamp":1768286123000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1753749\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1753749"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1753749","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"article-number":"1753749"}}